grant
Blood amyloid, tau, and neurodegeneration biomarkers and prediction of clinical onset, cognitive decline, and dementia diagnosis
Organization WASHINGTON UNIVERSITYLocation SAINT LOUIS, UNITED STATESPosted 30 Sept 2008Deadline 31 May 2029
NIHUS FederalResearch GrantFY2025A β-42A β42A-beta 42A-beta42AD dementiaAD pathologyAbeta-42Abeta42AbscissionAccelerationAccuracy of DiagnosisAddressAgeAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's amyloidAlzheimer's biomarkerAlzheimer's diagnosisAlzheimer's disease biological markerAlzheimer's disease diagnosisAlzheimer's disease pathologyAlzheimer's disease testAlzheimer's pathologyAlzheimer's testAlzheimers DementiaAlzheimer’s biological markerAlzheimer’s disease biomarkerAmentiaAmyloidAmyloid (Aβ) plaquesAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid PlaquesAmyloid Protein A4Amyloid SubstanceAmyloid beta-42Amyloid beta-ProteinAmyloid beta42Amyloid βAmyloid β-42Amyloid β-PeptideAmyloid β-ProteinAmyloid β42Amyloidβ-42Amyloidβ42AβAβ-42Aβ42BiologicalBiological MarkersBiologyBloodBlood PlasmaBlood Reticuloendothelial SystemBlood SampleBlood TestsBlood specimenCaringClinicClinicalClinical ResearchClinical StudyClinical TreatmentClinical TrialsClinical assessmentsCognitionCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCommunitiesDataDementiaDepositDepositionDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseDisorderDisturbance in cognitionDrugsDysfunctionEarly DiagnosisEducationEducational aspectsElectronic Health RecordElectronicsEnrollmentExcisionExtirpationFunctional disorderGeneral PopulationGeneral PublicGeneticGoalsGoldHematologic TestsHematological TestsHematology TestingImageImpaired cognitionLightLong-term cohortLongitudinal cohortLumbar PunctureMT-bound tauMeasuresMedicalMedical centerMedicationNerve DegenerationNeuritic PlaquesNeurofibrillary TanglesNeuron DegenerationPETPET ScanPET imagingPETSCANPETTParticipantPathologyPatientsPerformancePersonsPharmaceutical PreparationsPhosphorylation SitePhotoradiationPhysiopathologyPlasmaPlasma SerumPopulationPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPreventionPrimary Senile Degenerative DementiaPropertyProspective StudiesProteinsRaceRacesRad.-PETRemovalReportingResearchReticuloendothelial System, Serum, PlasmaRiskSenile PlaquesSensitivity and SpecificitySocio-economic statusSocioeconomic StatusSpecialtySpinal PunctureSurgical RemovalSymptomsTauopathiesTestingUnderrepresented GroupsUnderrepresented PopulationsWorka beta peptideabetaaccurate diagnosisaccurate diagnosticsagesamyloid betaamyloid beta plaqueamyloid pathologyamyloid-b plaqueamyloid-b proteinaβ plaquesbeta amyloid fibrilbio-markersbiologicbiologic markerbiomarkerblood-based biomarkerblood-based markerclinical diagnosisclinical interventionclinical predictorsclinical therapyco-morbidco-morbiditycognitive assessmentcognitive changecognitive dysfunctioncognitive losscognitive testingcohortcomorbiditycored plaquecostdemographicsdevelopmentaldiagnostic accuracydiffuse plaquedrug/agentearly detectioneffective therapyeffective treatmentelectronicelectronic deviceelectronic health care recordelectronic health medical recordelectronic health plan recordelectronic health registryelectronic medical health recordenrollfeasibility testingimaginglow SESlow socio-economic positionlow socio-economic statuslow socioeconomic positionlow socioeconomic statusmedical specialtiesmicrotubule bound taumicrotubule-bound tauneural degenerationneurodegenerationneurodegenerativeneurofibrillary degenerationneurofibrillary lesionneurofibrillary pathologyneurofilamentneurological degenerationneuronal degenerationneuropathologic tauneuropathological taunew markernovelnovel biomarkernovel markerp-taup-τpathophysiologypatient populationphospho-tauphospho-τphosphorylated taupolygenetic risk scorespolygenic risk scorepopulation basedpositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypost-translational modification of tauposttranslational modification of tauprimary degenerative dementiaprognosticracialracial backgroundracial originrate of changeresectionsenile dementia of the Alzheimer typesexsocio-economic positionsocioeconomic positionsoluble amyloid precursor proteintangletautau Proteinstau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau factortau induced degenerationtau induced neurodegenerationtau mediated neurodegenerationtau neurodegenerative diseasetau neuropathologytau pathologytau pathophysiologytau phosphorylationtau posttranslational modificationtau proteinopathytau related neurodegenerationtau-1tau-induced pathologytauopathic neurodegenerative disordertauopathytest for Alzheimertooltrial regimentrial treatmentunder representation of groupsunder represented groupsunder represented peopleunder represented populationsunderrepresentation of groupsunderrepresented peopleτ Proteinsτ phosphorylation
Description preview
PROJECT SUMMARY
In order to accelerate observational clinical studies and trials and to identify appropriate patients for treatments,
highly accurate and accessible diagnostic tests for Alzheimer's disease (AD) are needed. Clinical assessments
alone are insufficient for accurate diagnoses, and the current gold standard tests for AD (CSF and PET)…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click